Gilead Sciences (GILD)
$77.83 2.51 (3.33%)
19:59 EDT GILD Stock Quote Delayed 30 Minutes
Previous Close $77.83
Market Cap 101.20B
PE Ratio 29.59
Volume (Avg. Vol.) 24.38M
Day's Range 74.61 - 78.12
52-Week Range 60.89 - 85.97
Dividend & Yield 2.23 (2.87%)
GILD Stock Predictions, Articles, and Gilead Sciences News
- From InvestorPlace
- From the Web
With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.
Gilead is moving into commercial production of Remdesivir, a COVID-19 treatment with an aggressive pricing model, but other biotech solutions could come out ahead; it's early days still.
GILD stock has been rallying, but it has been running out of momentum lately. Just don't lose focus on the positives for Gilead.
Nvidia caught a huge price target increase, while Apple looks to reopen its stores. Here's what happened in the stock market today.
Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.
With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong
Under any other circumstance, sell in May and go away may be considered a sound strategy. In this crisis, though, you may want to keep these stocks to buy for the long haul.
Could the S&P 500 be heading for 3,000? Plus, Chesapeake Energy is on the brink. Here's what else happened in the stock market today.
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
With some countries and states moving to reopen businesses, Capital One Financial Corporation (NYSE:COF) is an excellent target for a bullish put write.
By David Moadel
Thursday's big stock charts feature names that moved sharply on red-hot news stories
The remdesivir news took precedent over headlines about first-quarter GDP, which contracted 4.8%, or the worst shrinkage experienced by the world's largest economy since the dark days of the global financial crisis.
Google's earnings boosted the Nasdaq, while small-cap stocks continue to roar to life. Here's what happened in the stock market today.
Gilead released more positive data on its Covid-19 treatment, remdesivir, laying the groundwork for bigger gains ahead for GILD stock.
Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.
GM is cutting its dividend and Apple is delaying iPhone production. Here's what happened in the stock market today.
Late last week, a Financial Times report suggested that Gilead’s coronavirus candidate drug remdesivir was not effective. However, the narrative for GILD stock requires a much broader context.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
From Real Money
Navellier RatingsPowered by Portfolio Grader